Oragenics has announced the successful completion of an independently conducted, randomized, double-blind clinical trial of EvoraKids oral probiotic.
The study, which included 60 6- to 12-year-old children prone to caries, demonstrated a statistically significant decrease from baseline levels of the key oral bacterial species mutans streptococci and lactobacilli after a four-week treatment with EvoraKids. No adverse events from the use of EvoraKids were reported during the trial.
"Oragenics is encouraged by the results of this first independent study in children employing the company's proprietary blend of oral care probiotics," said CEO John Bonfiglio, PhD. "These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators."
Trial details and results will be presented on March 21, 2012, at the American Association for Dental Research meeting in Tampa, FL. The study, entitled "DNA-PCR and CRT Results in Children after Probiotic Use," will be part of a scientific session devoted to clinical studies related to dental cariology.
